Drugs / 610
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06680947 | Dec 2024 → Feb 2027 expected | asthma | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 610 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06680947 ↗ |
| Action | Inhibit | “Recombinant Anti-IL-5 Humanized Monoclonal Antibody Therapy” NCT06680947 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-IL-5 Humanized Monoclonal Antibody Therapy” NCT06680947 ↗ |
| Route | Subcutaneous | “Subcutaneously injection.” NCT06680947 ↗ |
| Target | IL5 | “Recombinant Anti-IL-5 Humanized Monoclonal Antibody Therapy” NCT06680947 ↗ |